When vaccines have been administered and COVID-19 is at bay, hopefully the vaccine makers and their partners will provide the entire drug development and manufacturing industry with details about the challenges they encountered in their supply chains.
We verified through a dismaying pandemic, outsourcing drug development and manufacturing is sustainable. But this annus horribilis also laid bare supply-chain vulnerabilities. Here’s the best and worst of your 2020.
Joseph Graskemper of Translate Bio was recently involved in a process to create a V-PIP [virtual person-in-plant] at his CDMO. Turns out to be something that should carry on post-COVID-19, and prompt readers and your service providers to some ingenuity of your own.
The tragic combination of infectiousness and lethality of SARS-CoV-2 and COVID-19 has been the greatest public health emergency of the past 100 years. But there is a way forward through science, discovery, translation, and execution.
No biopharma start-up has been as misconstrued, hastily judged in strategy and capability, or even labeled “political.” Now Phlow Corporation’s CEO Eric Edwards sets the record straight in an exclusive interview.
As the pharma industry scrambles to develop one or more viable COVID-19 vaccines, the greatest hurdle to immunizing the world’s population is the manufacture of billions of doses in parallel. In response to this challenge, vaccine developers are signing an unprecedented number of outsourcing agreements with CMOs and other service providers.